文献速递糖尿病

长期使用二甲双胍与2型糖尿病患者肺炎及肺炎相关死亡风险:一项注册队列研究

Long-term metformin use and risk of pneumonia and related death in type 2 diabetes: a registry-based cohort study.
PubMed 文献 · Diabetologia · 2021-04-12

该研究基于香港糖尿病注册队列,纳入22,638例2型糖尿病患者,采用重叠倾向评分加权分析,发现与使用其他降糖药者相比,二甲双胍使用者首次肺炎住院风险(HR 0.63,95%CI 0.52-0.77)和肺炎相关死亡风险(HR 0.49,95%CI 0.33-0.73)均显著降低。研究提示长期二甲双胍使用与肺炎风险降低相关。

要点

  • 二甲双胍使用者首次肺炎住院风险显著低于其他降糖药使用者(HR 0.63)。
  • 二甲双胍使用者肺炎相关死亡风险显著降低(HR 0.49)。
  • 二甲双胍相关乳酸酸中毒发生率为2.5/10万人年。

核心结论

  • 长期使用二甲双胍与2型糖尿病患者肺炎及肺炎相关死亡风险降低相关。

研究设计与样本

  • 回顾性分析香港糖尿病注册队列中2001-2018年入组的22,638例2型糖尿病患者,随访至2019年12月31日,采用重叠倾向评分加权平衡基线特征。

主要发现

  • 在平均随访7.5年中,二甲双胍使用者对比其他降糖药使用者,首次肺炎住院的HR为0.63(95%CI 0.52,0.77),肺炎相关死亡的HR为0.49(95%CI 0.33,0.73)。
  • 按性别和肾功能分层后结果相似,惩罚样条分析显示二甲双胍暴露时间比例与肺炎事件呈负相关。
  • 二甲双胍使用者首次肺炎住院时中性粒细胞/淋巴细胞比值较低(均值[95%CI]:12.8[12.1,13.5] vs 14.8[12.3,17.3],p=0.032)。
  • 二甲双胍相关乳酸酸中毒发生率为2.5/10万人年。
  • 新发二甲双胍使用者对比其他降糖药使用者亦观察到肺炎事件风险降低。

临床怎么用

  • 对于2型糖尿病患者,长期二甲双胍治疗可能与肺炎住院及肺炎相关死亡风险降低相关,临床可结合患者情况考虑其潜在获益。

局限性

  • 本研究为回顾性队列研究,可能存在残余混杂。
  • 结果是否适用于其他呼吸道感染尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The long-term effects of metformin in individuals with type 2 diabetes who are at increased risk of severe respiratory infections are unknown. This study aimed to evaluate the effects of metformin use on the risk of first pneumonia hospitalisation and pneumonia-related death in a cohort of Chinese individuals with type 2 diabetes. METHODS: We performed a retrospective analysis of a consecutive cohort of 22,638 individuals with type 2 diabetes in the Hong Kong Diabetes Register enrolled between 2001 and 2018, with follow-up until 31 December 2019. Overlap propensity-score weighting was performed to balance baseline characteristics. RESULTS: Of 22,638 individuals with type 2 diabetes, after excluding those who had not been prescribed any glucose-lowering drugs (GLDs) and/or with eGFR ≤30 ml min-1 [1.73 m]-2 or treated by dialysis and/or treated with insulin at baseline, we identified 15,784 either prevalent or incident metformin users and 917 users of other GLDs during a mean follow-up period of 7.5 years. Overlap-weighted analysis showed an HR of 0.63 (95% CI 0.52, 0.77) for first pneumonia hospitalisation and 0.49 (95% CI 0.33, 0.73) for pneumonia-related death in metformin users vs users of other GLDs; similar observations resulted following stratification by sex and kidney function. There was also a negative association between metformin exposure over time (proportion of duration of metformin prescriptions during the total follow-up time) and pneumonia events using the penalised spline analysis. Metformin users had a lower neutrophil/lymphocyte ratio at first pneumonia hospitalisation vs non-metformin users (mean [95% CI]: 12.8 [12.1, 13.5] vs 14.8 [12.3, 17.3], p = 0.032). The rate of metformin-associated lactic acidosis was 2.5 per 100,000 person-years. The lower risk of pneumonia events was also observed among incident metformin users vs other GLD users. CONCLUSIONS/INTERPRETATION: Long-term use of metformin was associated with reduced risk of pneumonia and pneumonia-related death among Chinese individuals with diabetes. The relevance of these results to other respiratory infections merits further investigation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Yang A, Shi M, Wu H, et al. Long-term metformin use and risk of pneumonia and related death in type 2 diabetes: a registry-based cohort study. Diabetologia. 2021. PMID: 33844069. doi:10.1007/s00125-021-05452-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。